Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;25(3):148-155.
doi: 10.1111/1751-2980.13265. Epub 2024 Apr 16.

Application of furazolidone in Helicobacter pylori infection eradication

Affiliations
Review

Application of furazolidone in Helicobacter pylori infection eradication

Ying Ying Han et al. J Dig Dis. 2024 Mar.

Abstract

Increasing antibiotic resistance is the primary reason for treatment failure of Helicobacter pylori (H. pylori) infection. To enhance the eradication rate, minimize the development of secondary resistance, and alleviate the socioeconomic burden, it is crucial to select H. pylori-sensitive antibiotics carefully. Furazolidone has been used for H. pylori eradication in developing countries for decades due to its affordability and low resistance rate. Numerous studies have demonstrated that furazolidone-containing regimens are more efficacious than those containing other antibiotics, as both first- and second-line therapies, and are also well tolerated. However, utility of furazolidone is restricted or not optimal in certain countries due to its infrequent but potentially severe adverse effects. The decision to discontinue usage of furazolidone because of concerns regarding adverse effects may be misguided. Here we comprehensively reviewed the studies on furazolidone at different dosages and treatment durations for H. pylori eradication. Further research on the mechanisms of action and clinical trials of furazolidone are of great practical importance.

Keywords: Helicobacter pylori; eradication; furazolidone; safety.

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta‐analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553‐564.
    1. Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta‐analysis. Gastroenterology. 2017;153(2):420‐429.
    1. Malfertheiner P, Megraud F, O'Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6‐30.
    1. Tacconelli E, Carrara E, Savoldi A, et al; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic‐resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318‐327.
    1. Gao HJ, Zhong ZS, Yan LJ, Zhang XY, Shen WX. Personalized therapy for Helicobacter pylori on initial treatment: the initial treatment is the decisive battle. Natl Med J China. 2022;102(22):1631‐1634. [in Chinese].

MeSH terms

LinkOut - more resources